Stoke Therapeutics (STOK) Operating Income (2022 - 2025)
Historic Operating Income for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to -$43.1 million.
- Stoke Therapeutics' Operating Income fell 4362.23% to -$43.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.2 million, marking a year-over-year increase of 12318.44%. This contributed to the annual value of -$101.4 million for FY2024, which is 1167.61% up from last year.
- As of Q3 2025, Stoke Therapeutics' Operating Income stood at -$43.1 million, which was down 4362.23% from -$27.3 million recorded in Q2 2025.
- In the past 5 years, Stoke Therapeutics' Operating Income registered a high of $111.2 million during Q1 2025, and its lowest value of -$43.1 million during Q3 2025.
- Over the past 4 years, Stoke Therapeutics' median Operating Income value was -$27.2 million (recorded in 2023), while the average stood at -$18.6 million.
- Within the past 5 years, the most significant YoY rise in Stoke Therapeutics' Operating Income was 49207.67% (2025), while the steepest drop was 4362.23% (2025).
- Stoke Therapeutics' Operating Income (Quarter) stood at -$27.2 million in 2022, then dropped by 8.87% to -$29.6 million in 2023, then skyrocketed by 53.85% to -$13.7 million in 2024, then tumbled by 215.62% to -$43.1 million in 2025.
- Its Operating Income was -$43.1 million in Q3 2025, compared to -$27.3 million in Q2 2025 and $111.2 million in Q1 2025.